Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)
Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Summary
This study will evaluate the effect and safety of 608 in patients with nr-axSpA.
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of 608 in Patients With Non-radiographic Axial Spondyloarthritis (Nr-axSpA)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
180
Start Date
2024-03-22
Completion Date
2025-11-30
Last Updated
2025-03-11
Healthy Volunteers
No
Conditions
Interventions
608
608 subcutaneous (SC) injection.
608
608 subcutaneous (SC) injection.
Placebo
Placebo subcutaneous (SC) injection.
Locations (6)
Site 01
Beijing, Beijing Municipality, China
Site 03
Beijing, Beijing Municipality, China
Site 05
Chongqing, Chongqing Municipality, China
Site 02
Zhengzhou, Henan, China
Site 04
Nanjing, Jiangsu, China
Site 06
Shenzhen, Shenzhen, China